Cambridge, MA, May 8, 2007 - U.S. Genomics announced today that Salvatore J. Salamone, Ph.D., has joined the company's Board of Directors. Dr. Salamone is presently also Chairman and Chief Executive Officer of Saladax BioMedical Inc., a developer of chemotherapy monitoring assays http://www.saladax.com/. Previously, he was Vice President of R&D at Roche Diagnostics and Senior Vice President of R&D at Orasure Technologies.
At Roche Diagnostics, Dr. Salamone was responsible for North American Research and Development efforts for the Laboratory Systems division. Dr. Salamone's efforts during his 17-year tenure at Roche resulted in the launch of seven major reagent product platforms, comprised of over 70 products and more than 200 instrument applications.
John J. Canepa, U.S. Genomics President and CEO commented, "We are excited to welcome Dr. Salamone to U.S. Genomics' Board of Directors. He brings a unique perspective and business savvy to the challenges and opportunities facing U.S. Genomics. We look forward to his expert guidance and input as we develop the applications for our genomic mapping and other single molecule detection technologies in the field of human diagnostics."
Dr. Salamone commented, “I look forward to working with the team at U.S. Genomics on its single molecule technologies. The novel aspects of this technology enable it to provide unprecedented information in the field of Molecular Diagnostics. The Company's high throughput genomic mapping technology has great potential for several human diagnostic applications, including rapid and broad spectrum infectious agent detection without culture or amplification.”
In conjunction with this appointment, J. Craig Venter has stepped down from the Board.
About U.S. Genomics, Inc.
U.S. Genomics is pioneering single molecule biology technologies for biodefense and diagnostics applications by combining advances in microfluidics, optical engineering, and novel labeling strategies. Using its DNA mapping technology, the Company is developing sophisticated biological sensors for the detection and identification of pathogens and biomarkers in the air, human serum and other biologically relevant materials. The Company's biodefense focus on airborne pathogens has been funded in part by $35 million in contracts from the U.S. Department of Homeland Security. The company's Trilogy® platform enables the direct detection and analysis of individual molecules of DNA, RNA, and proteins without the need for amplification. U.S. Genomics' portfolio of products will further a greater understanding of genetics and disease pathways and will ultimately lead to more effective therapeutics, diagnostics, and biodefense applications. For more information, please visit http://www.usgenomics.com/.
At U.S. Genomics
President and CEO